SCHEMBL28854828

SCHEMBL28854828

CC(NP(=O)(Oc1ccc([N+](=O)[O-])cc1)Oc1ccc([N+](=O)[O-])cc1)C(=O)OC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP19A1 P11511 1/20 0.39
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26294735 1.00 NPC1 (0.45) NPC1RAB9APOLBCES2CES1
SCHEMBL16822791 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL28854979 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL26276587 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL16554112 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL16554037 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL16554039 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL16554114 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL16566138 0.97 POLB (0.43) NPC1RAB9APOLBCES2CES1
SCHEMBL30160662 0.96 CES2 (0.43) NPC1RAB9APOLBCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115175735-A Antiviral compounds 吉利德科学公司 2022-10-11 — — CN disclosed
Send feedback